Abstract:A 43-year-old female nonsmoker patient presented to our hospital in September 2014 with a 2-month history of coughing and a 1-month history of back pain. A bronchoscopic biopsy showed that the patient had a stage IV (T2N2M1) lung adenocarcinoma (Fig. 1) and magnetic resonance imaging revealed lumbar and brain metastases. The patient was treated with 2 cycles of chemotherapy (pemetrexed and cisplatin), followed by bone radiotherapy (T8-T10, DT3000 cGy) and whole-brain radiotherapy (DT3000 cGy). The efficacy was stable disease. The amplification refractory mutation system method showed that the adenocarcinoma cells harbored an exon 19 deletion of the EGFR gene. We analyzed the initial tissue upon which was only found EGFR p.E746_S752delinsV by next-generation sequencing (3D Medicines, Shanghai, China). Thus, the patient was administrated erlotinib (150 mg daily) from November 2014 to August 2017. Thus far, no progression of the original lung mass has been identified; however, multiple bone, liver, and adrenal metastases were noted, and the brain metastases had enlarged according to the Response Evaluation Criteria in Solid Tumors version 1.1 in August 2017. Hence, we concluded that the patient had EGFR–tyrosine kinase inhibitor (TKI) resistance. Therefore, a repeat liquid biopsy was performed, which showed an acquired MET-UBE2H fusion gene by next-generation sequencing (3D Medicines) (Fig. 2). The disease progressed, so the patient was switched to crizotinib (250 mg twice daily) in September 2017 (Fig. 3A). She achieved a partial response and progression-free survival at more than 6.5 months (Fig. 3B).Figure 2MET-UBE2H fusion is clinically actionable. (A) the Integrative Genomics Viewer snapshot of MET-UBE2H. (B) Schematic representation of the MET-UBE2H fusion protein domain structure.View Large Image Figure ViewerDownload Hi-res image Download (PPT)Figure 3Computed tomography (CT) scans show: (A) before crizotinib therapy, and (B) CT of the chest showed partial response after months of crizotinib treatment.View Large Image Figure ViewerDownload Hi-res image Download (PPT) We presented the first case involving a patient with the MET-UBE2H fusion gene who experienced a dramatic and durable antitumor response to crizotinib after acquired resistance to EGFR-TKI. We assume that MET-UBE2H is a novel resistance gene rearrangement to EGFR-TKI which has not been described. Nowadays, there are two chief mechanisms of resistance that have been reported: approximately 50% of patients develop secondary EGFR mutations; and 15% to 20% of patients experience MNNG HOS Transforming gene (MET) amplification.1Kobayashi S. Boggon T.J. Dayaram T. et al.EGFR mutation and resistance of non–small-cell lung cancer to gefitinib.N Engl J Med. 2005; 24: 786-792Crossref Scopus (3476) Google Scholar MET directly activates downstream signaling pathways of EGFR through upregulation and activation of P13K/AKT signaling, leading to tumor resistance to EGFR-TKI.2Engelman J.A. Zejnullahu K. Mitsudomi T. et al.MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.Science. 2007; 18: 1039-1043Crossref Scopus (3900) Google Scholar The patient described herein showed a significant response to crizotinib. Crizotinib inhibits MET kinase and blocks the MET signaling pathway, therefore limiting the expression of the MET fusion gene.3Reck M. Popat S. Reinmuth N. et al.Metastatic non–small cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Ann Oncol. 2014; 25: 27-39Crossref Scopus (588) Google Scholar, 4Gridelli C. Rossi A. Airoma G. et al.Treatment of pulmonary neuroendocrine tumours: state of the art and future developments.Cancer Treat Rev. 2012; 25: 466-472Google Scholar Recent research has focused on MET exon 14 alterations, but the treatment of more complex structural rearrangements has not been established. In addition, KIF5B and STARD3NL have been observed as a fusion partner for MET. It has been reported that KIF5B-MET and STARD3NL-MET gene fusion benefits from treatment with crizotinib.5Plenker D. Bertrand M. de Langen A.J. et al.Structural alterations of MET trigger response to MET kinase inhibition in lung adenocarcinoma patients.Clin Cancer Res. 2018; 15: 1337-1343Crossref Scopus (49) Google Scholar We recommend that more effort be exerted to explore the mechanism underlying resistance to EGFR-TKI and treatment of complex structural MET gene rearrangements. Crizotinib may be used to overcome EGFR-TKI resistance conferred by MET gene rearrangements. In such a situation, a second biopsy should be routinely performed after acquisition of resistance to the EGFR-TKI to examine the MET gene rearrangements, as well as other mechanisms of resistance, if possible. This study was supported in part by grants from the Science and Technology Planning Project of Zhejiang Province (2015C33194) and the National Clinical Key Specialty Construction Program (2013).

Heterogeneity of the Resistance to Gefitinib Treatment in a Non‐small Cell Lung Cancer Patient with Active Epidermal Growth Factor Receptor Mutation

Mefatinib As First-Line Treatment of EGFR Sensitizing Mutation-Positive Non-Small-cell Lung Cancer: A Phase III Efficacy and Biomarker Study.

Patient with EGFR-mutant lung cancer harboring de novo MET amplification successfully treated with gefitinib combined with crizotinib

Heterogeneity Response to Afatinib in Gastric Cancer Patient with Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations: a Case Report

Case Report: Heterogeneity of Resistance Mechanisms in Different Lesions Co-Mediate Acquired Resistance to First-Line Icotinib in EGFR Mutant Non-Small Cell Lung Cancer

HER2 Overexpression Reverses the Relative Resistance of EGFR-mutant H1975 Cell Line to Gefitinib.

Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib

Detection of EGFR Mutations in Plasma Circulating Tumour DNA As a Selection Criterion for First-Line Gefitinib Treatment in Patients with Advanced Lung Adenocarcinoma (BENEFIT): a Phase 2, Single-Arm, Multicentre Clinical Trial

Restoration of gefitinib efficacy following chemotherapy in a patient with metastatic non-small cell lung cancer.

Epidermal growth factor receptor-mutated lung carcinomas with insufficient response to epidermal growth factor receptor inhibitors

Effect of Gefitinib Challenge to Initial Treatment with Non-Small Cell Lung Cancer

Association Of Initial Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment And EGFR Exon 19 Deletion With Frequency Of The T790M Mutation In Non-Small Cell Lung Cancer Patients After Resistance To First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

EP1.14-46 the KIF5B-RET Fusion As a Novel Mechanism of Acquired EGFR Tyrosine Kinase Inhibitor Resistance in Lung Adenocarcinoma

EGFR plus MET Targeted Therapies for Overcoming Treatment Resistance in EGFR-Mutant Non-Small Cell Lung Cancer: A Case Report

MET-UBE2H Fusion As a Novel Mechanism of Acquired EGFR Resistance in Lung Adenocarcinoma

Three Novel EGFR Mutations (750_758del, I759S, T751_I759delinsS) in One Patient with Metastatic Non-Small Cell Lung Cancer Responding to Osimertinib: A Case Report

Resistance to Epithelial Growth Factor Receptor Tyrosine Kinase Inhibitors in a Patient with Transformation from Lung Adenocarcinoma to Small Cell Lung Cancer: A Case Report

EGFR-tyrosine Kinase Inhibitor Treatment in a Patient with Advanced Non-Small Cell Lung Cancer and Concurrent Exon 19 and 21 EGFR Mutations: A Case Report and Review of the Literature.

Different First Line EGFR-TKI Regimen and the Clearance of EGFR Sensitive Mutation in Acquired EGFR-TKI Resistant Lung Adenocarcinoma Patients

[Management of a patient with a double EGFR and MET anomaly by combined treatment]

Role of Allogeneic Natural Killer T Cells in the Treatment of a Patient with Gefitinib-Sensitive Lung Adenocarcinoma.